OSCR

Esketamine Attenuates Postoperative Neurocognitive Disorder in Aged Mice: Associations with Bioenergetic Remodeling in Hippocampal CD11b-Enriched Cell Fractions and Glycolysis-Related Signaling.

Overview

Authors: Di Liu1,2, Guangchun Li3, Hui Huang1, Yong Yang1, Fei Jiang1, Yue Zhang1
ORCID iDs: Di Liu, Fei Jiang
  1. Anesthesia Surgery Center, the First People’s Hospital of Neijiang, Neijiang, Sichuan, 641000, People’s Republic of China
  2. Department of Anesthesiology, The Second Clinical College of Chongqing Medical University, Chongqing, People’s Republic of China
  3. Yulin City Center for Disease Control and Prevention, Yulin, Guangxi, People’s Republic of China
Journal: Drug design, development and therapy, volume 20, article 627186
Dates: received 5 June 2026; accepted 7 August 2026; published online 25 August 2026
Type: Research article · Language: English
License: CC BY-NC
Identifiers: DOI 10.2147/dddt.s627186 · PMID 42668954 · PMCID PMC13525777 · OpenAlex W7204156430
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), mouse (organism), Alzheimer's / dementia (population), cellular / molecular (subfield)
Methods: Spectral & time-frequency, Statistics
Keywords: esketamine, postoperative neurocognitive disorder, microglia, bioenergetics, glycolysis, hippocampus
MeSH: CD11b Antigen*, Glycolysis*, Hippocampus*, Ketamine*, Postoperative Cognitive Complications*, Animals, Disease Models, Animal, Energy Metabolism, Male, Mice, Mice, Inbred C57BL, Signal Transduction (* major topic)
Topic: Intensive Care Unit Cognitive Disorders (Critical Care and Intensive Care Medicine, Medicine), according to OpenAlex
Funding: Health Commission of Sichuan Province; Sichuan Province Science and Technology Support Program
Citations: not cited yet (Europe PMC); 38 references in the paper

Abstract

Background: Postoperative neurocognitive disorder (PND) is a clinically important complication in older surgical patients. Microglial inflammatory activation is frequently accompanied by altered cellular metabolism, but whether esketamine-associated neuroprotection is accompanied by bioenergetic changes in hippocampal CD11b-enriched cell fractions remains incompletely understood.

Methods: A tibial fracture model was used to induce PND in aged male mice. The public hippocampal transcriptomic dataset GSE165798 was analyzed as an exploratory, hypothesis-generating screen. Independent animal cohorts were evaluated using behavioral testing, whole-hippocampal qRT-PCR and biochemical assays, immunofluorescence, transmission electron microscopy, and Seahorse extracellular flux analysis of hippocampal CD11b-enriched cell fractions. Early hippocampal IL-1β was measured at 24 h in a tissue-analysis cohort. In a separate contemporaneous five-group pharmacological cohort, behavioral outcomes were assessed before hippocampal IL-1β and TNF-α measurement on postoperative day 14. Systemic 2-DG was used as a non-cell-specific pharmacological probe of associations between glycolytic inhibition and selected outcomes.

Results: Exploratory transcriptomic analysis suggested coordinated glycolysis-related and inflammatory changes in the PND hippocampus. In independent cohorts, esketamine improved spatial learning and memory, attenuated the early 24-h hippocampal IL-1β elevation, preserved synaptic ultrastructure, and reduced glycolysis-related molecular and biochemical changes measured in whole hippocampal tissue. In hippocampal CD11b-enriched cell fractions collected at 24 h, esketamine was associated with lower glycolytic activity and improved mitochondrial respiratory parameters. In the separate pharmacological cohort, hippocampal IL-1β and TNF-α were measured on day 14 after behavioral testing. Systemic 2-DG was associated with selected behavioral and day-14 cytokine differences relative to untreated PND mice; a contemporaneous Control + 2-DG group was included. In direct comparisons of the esketamine and 2-DG groups, the mean differences were −0.40s for time in the target quadrant (95% CI, −4.35 to 3.55; Tukey-adjusted P = 0.9984), 4.71 pg/mg protein for IL-1β (95% CI, −8.99 to 18.41; Tukey-adjusted P = 0.8588), and 2.38 pg/mg protein for TNF-α (95% CI, −12.69 to 17.45; Tukey-adjusted P = 0.9908). These nonsignificant comparisons neither establish therapeutic equivalence nor demonstrate that glycolytic inhibition mediates the effects of esketamine.

Conclusion: Esketamine attenuated surgery-induced cognitive impairment, the early 24-h hippocampal IL-1β elevation, and synaptic ultrastructural damage in aged mice. In a separate pharmacological cohort assessed on day 14, esketamine and systemic 2-DG were each associated with lower hippocampal IL-1β and TNF-α than untreated PND. These findings were accompanied, in separate experimental cohorts, by improved bioenergetic profiles in hippocampal CD11b-enriched cell fractions and reduced glycolysis-related markers in whole hippocampal tissue. The data support associations among esketamine treatment, metabolic-inflammatory remodeling, and neuroprotection, but do not establish a microglia-specific HK2/PKM2-dependent mechanism, a causal role for glycolysis, or mechanistic equivalence between esketamine and 2-DG.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data Sharing Statement

The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. The transcriptomic dataset GSE165798 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE165798) is publicly available in the NCBI Gene Expression Omnibus repository. RT-qPCR primer sequences are provided in Table S1 (http://ttps://www.dovepress.com/article/supplementary_file/627186/627186 Supplementary Material.docx) in the Supplementary Material (http://ttps://www.dovepress.com/article/supplementary_file/627186/627186 Supplementary Material.docx).

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

  • Funding: added Health Commission of Sichuan Province; Sichuan Province Science and Technology Support Program

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 6 authors, 6 keywords, 12 MeSH terms, 38 references.

Cite

This paper

Liu, D., Li, G., Huang, H., Yang, Y., Jiang, F., & Zhang, Y. (2026). Esketamine Attenuates Postoperative Neurocognitive Disorder in Aged Mice: Associations with Bioenergetic Remodeling in Hippocampal CD11b-Enriched Cell Fractions and Glycolysis-Related Signaling. Drug design, development and therapy, 20, 627186. https://doi.org/10.2147/dddt.s627186

BibTeX

@article{liu2026esketamine,
author = {Liu, Di and Li, Guangchun and Huang, Hui and Yang, Yong and Jiang, Fei and Zhang, Yue},
title = {{Esketamine Attenuates Postoperative Neurocognitive Disorder in Aged Mice: Associations with Bioenergetic Remodeling in Hippocampal CD11b-Enriched Cell Fractions and Glycolysis-Related Signaling}},
journal = {Drug design, development and therapy},
year = {2026},
month = aug,
volume = {20},
pages = {627186},
publisher = {Dove Press},
issn = {1177-8881},
doi = {10.2147/dddt.s627186},
url = {https://doi.org/10.2147/dddt.s627186},
pmid = {42668954},
pmcid = {PMC13525777}
}

RIS

TY - JOUR
AU - Liu, Di
AU - Li, Guangchun
AU - Huang, Hui
AU - Yang, Yong
AU - Jiang, Fei
AU - Zhang, Yue
TI - Esketamine Attenuates Postoperative Neurocognitive Disorder in Aged Mice: Associations with Bioenergetic Remodeling in Hippocampal CD11b-Enriched Cell Fractions and Glycolysis-Related Signaling
T2 - Drug design, development and therapy
J2 - Drug Des Devel Ther
PY - 2026
DA - 2026/08/25
VL - 20
SP - 627186
SN - 1177-8881
PB - Dove Press
DO - 10.2147/dddt.s627186
UR - https://doi.org/10.2147/dddt.s627186
LA - en
ER -

CSL-JSON

{
"id": "10.2147/dddt.s627186",
"type": "article-journal",
"title": "Esketamine Attenuates Postoperative Neurocognitive Disorder in Aged Mice: Associations with Bioenergetic Remodeling in Hippocampal CD11b-Enriched Cell Fractions and Glycolysis-Related Signaling",
"container-title": "Drug design, development and therapy",
"author": [
{
"family": "Liu",
"given": "Di"
},
{
"family": "Li",
"given": "Guangchun"
},
{
"family": "Huang",
"given": "Hui"
},
{
"family": "Yang",
"given": "Yong"
},
{
"family": "Jiang",
"given": "Fei"
},
{
"family": "Zhang",
"given": "Yue"
}
],
"container-title-short": "Drug Des Devel Ther",
"volume": "20",
"page": "627186",
"DOI": "10.2147/dddt.s627186",
"PMID": "42668954",
"PMCID": "PMC13525777",
"ISSN": "1177-8881",
"publisher": "Dove Press",
"URL": "https://doi.org/10.2147/dddt.s627186",
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
25
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1111/cns.14902
Role of the circRNA_34414/miR-6960a-5p/SIRT3 axis in postoperative delirium via CA1 Vglut1+ neurons in older mice.
Journal: CNS neuroscience & therapeutics
In common: NCBI GEO GSE165798, mouse, cellular / molecular
[2] doi:10.1038/s42003-024-07425-6
Therapeutic potential of microglial SMEK1 in regulating H3K9 lactylation in cerebral ischemia-reperfusion.
Journal: Communications biology
In common: mouse, cellular / molecular, 4 references
[3] doi:10.1111/cpr.70221
SCD2 Alleviates Diabetes-Associated Cognitive Dysfunction by Improving Microglial Lipid Metabolism.
Journal: Cell proliferation
In common: mouse, cellular / molecular, 3 references
[4] doi:10.1186/s12974-025-03683-1
IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer's disease by regulating cGAS lactylation.
Journal: Journal of neuroinflammation
In common: Alzheimer's / dementia, mouse, cellular / molecular, 3 references
[5] doi:10.1038/s42003-026-09772-y
Microglial serine racemase knockout alleviates Alzheimer-like neuropathology and behavioral deficit via lactylation-mediated anti-inflammation.
Journal: Communications biology
In common: Alzheimer's / dementia, mouse, cellular / molecular, 3 references
[6] doi:10.2147/ijn.s621038
Protein Lactylation in Central Nervous System Diseases: Molecular Mechanisms and Targeted Therapeutic Strategies.
Journal: International journal of nanomedicine
In common: cellular / molecular, 3 references
[7] doi:10.1016/j.jare.2025.02.020
H4K12 lactylation potentiates mitochondrial oxidative stress via the Foxo1 pathway in diabetes-induced cognitive impairment.
Journal: Journal of advanced research
In common: mouse, cellular / molecular, 3 references
[8] doi:10.3892/ijmm.2026.5849
miR‑223‑3p promotes microglial lactylation and M1 polarization via the FBXW7/Notch1/Hes1/SIRT1 axis.
Journal: International journal of molecular medicine
In common: Alzheimer's / dementia, cellular / molecular, 3 references
[9] doi:10.1186/s13287-025-04571-4
Extracellular lactate improves neurogenesis by modulating H3K9 lactylation and SnoN expression under hypoxic conditions.
Journal: Stem cell research & therapy
In common: mouse, 3 references
[10] doi:10.2147/dddt.s510752
Identification of Key Genes in Esketamine's Therapeutic Effects on Perioperative Neurocognitive Disorders via Transcriptome Sequencing.
Journal: Drug design, development and therapy
In common: Alzheimer's / dementia, mouse, cellular / molecular, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.